Andrabi Syed Waseem, Jaffar Mir, Arora Puneet Rana
Milann-The Fertility Centre Division of Embryology New Delhi India Division of Embryology, Milann-The Fertility Centre, New Delhi, India.
Milann-The Fertility Centre Division of Embryology Bangalore India Division of Embryology, Milann-The Fertility Centre, Bangalore, India.
JBRA Assist Reprod. 2020 Jul 14;24(3):358-361. doi: 10.5935/1518-0557.20200054.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) widely known as COVID-19 was first reported in late December 2019, in China. Since then this novel coronavirus has spread throughout the world. Our return to normal life will not take long, for we are in a phase where the COVID-19 curve is stabilizing. ART services must return to operation, since infertility is also a disease and treatment has to start. Before resuming ART treatments, it is very important to consider local and national regulations. Change is mandatory, to set us back to successful ART treatment without compromising on quality, and to minimize the spread of COVID-19 among staff and patients; and for this we need to take measured and vigilant steps.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2),广为人知的新冠病毒,于2019年12月底在中国首次报告。自那时起,这种新型冠状病毒已蔓延至全球。我们恢复正常生活为期不远,因为我们正处于新冠病毒感染曲线趋于稳定的阶段。辅助生殖技术(ART)服务必须恢复运行,因为不孕症也是一种疾病,治疗必须开始。在恢复ART治疗之前,考虑当地和国家的法规非常重要。变革势在必行,以使我们在不影响质量的前提下恢复成功的ART治疗,并最大限度地减少新冠病毒在工作人员和患者之间的传播;为此,我们需要采取审慎且警惕的措施。